Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Industry: Biotechnology

Overview Zen Rating Price Value Growth Financials

Momentum Sentiment Forecast Dividends Due Diligence

Biotech is Zen Rated F and is the 137th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	ROE	ROA	ROCE	ROIC	D/E	Current Ratio	Gross Margin	Profit Margin	Operating Margin
ANIX	ANIXA BIOSCIENCES INC	$89.83M	-60.00%	-56.90%	-73.83%	-65.80%	0.12	9.35	N/A	N/A	N/A
ABSI	ABSCI CORP	$390.92M	-49.00%	-42.10%	-55.40%	-83.20%	0.19	4.67	100.00%	-2,274.10%	-2,260.06%
BIVI	BIOVIE INC	$15.09M	-141.00%	-98.30%	-94.41%	1,004.70%	0.07	16.94	N/A	N/A	N/A
FBRX	FORTE BIOSCIENCES INC	$48.05M	-132.00%	-103.10%	-67.60%	-1,017.80%	0.17	6.76	N/A	N/A	N/A
WHWK	WHITEHAWK THERAPEUTICS INC	$69.24M	-87.70%	-69.10%	-119.33%	-176.90%	0.34	3.59	88.40%	-245.10%	-244.53%
SEPN	SEPTERNA INC	$309.32M	-37.60%	-24.40%	-16.29%	-52.20%	0.09	27.77	100.00%	-6,678.90%	-6,725.21%
AKRO	AKERO THERAPEUTICS INC	$3.63B	-32.20%	-29.50%	-31.47%	-54.10%	0.10	19.38	N/A	N/A	N/A
AUTL	AUTOLUS THERAPEUTICS PLC	$375.24M	-43.80%	-26.20%	-29.06%	-42.60%	0.83	10.88	-12.50%	-2,180.50%	-2,073.52%
CMPX	COMPASS THERAPEUTICS INC	$257.21M	-34.80%	-32.60%	-37.54%	-41.80%	0.12	14.96	100.00%	-5,808.80%	-5,808.82%
IFRX	INFLARX NV	$100.90M	-60.70%	-51.80%	-74.43%	-83.40%	0.24	5.06	-1,900.80%	-27,785.00%	-27,769.42%
ELVN	ENLIVEN THERAPEUTICS INC	$928.14M	-29.20%	-27.40%	-28.66%	-47.40%	0.05	19.99	N/A	N/A	N/A
ICU	SEASTAR MEDICAL HOLDING CORP	$11.25M	N/A	-485.60%	1,126.11%	658.40%	-3.13	0.55	100.00%	-18,392.60%	-18,209.63%
FULC	FULCRUM THERAPEUTICS INC	$207.82M	-3.90%	-3.60%	-3.90%	-4.90%	0.07	22.63	100.00%	-12.20%	-12.16%
IBIO	IBIO INC	$10.47M	-99.20%	-61.70%	-112.30%	-123.00%	0.56	1.76	100.00%	-5,147.50%	-5,087.20%
VIR	VIR BIOTECHNOLOGY INC	$839.32M	-38.90%	-32.80%	-40.89%	-40.80%	0.22	8.71	98.90%	-703.40%	-704.95%
ALGS	ALIGOS THERAPEUTICS INC	$34.12M	-354.30%	-132.80%	-279.77%	-262.90%	-3.42	2.86	100.00%	-3,326.00%	-3,429.30%
MGX	METAGENOMI INC	$64.67M	-30.10%	-21.00%	-29.09%	-27.20%	0.38	6.91	100.00%	-149.30%	-159.81%
NVCT	NUVECTIS PHARMA INC	$232.98M	-160.80%	-102.80%	-195.61%	292.00%	0.92	2.09	N/A	N/A	N/A
CGON	CG ONCOLOGY INC	$2.05B	-14.70%	-14.40%	-12.00%	-17.70%	0.03	35.30	100.00%	-7,729.50%	-7,729.50%
EPIX	ESSA PHARMA INC	$80.79M	-24.60%	-23.90%	-26.15%	-94.10%	0.03	33.12	N/A	N/A	N/A
IRD	OPUS GENETICS INC	$43.21M	-180.20%	-132.30%	-225.02%	2,567.50%	1.68	3.24	100.00%	-523.40%	-523.40%
LIPO	LIPELLA PHARMACEUTICALS INC	$6.35M	-262.50%	-197.60%	-261.34%	-1,722.50%	0.39	3.47	100.00%	-935.20%	-935.25%
ACRV	ACRIVON THERAPEUTICS INC	$43.89M	-46.20%	-42.30%	-44.91%	-56.40%	0.11	10.55	N/A	N/A	N/A
KROS	KEROS THERAPEUTICS INC	$585.72M	-37.90%	-35.10%	-31.79%	-462.90%	0.08	21.45	100.00%	-5,277.50%	-5,269.10%
IRON	DISC MEDICINE INC	$1.71B	-25.20%	-23.60%	-22.90%	-54.20%	0.12	21.17	N/A	N/A	N/A
LQDA	LIQUIDIA CORP	$1.19B	-154.90%	-60.80%	-62.54%	-104.80%	1.98	4.43	58.00%	-931.70%	-842.44%
LGVN	LONGEVERON INC	$25.08M	-150.40%	-116.50%	-69.52%	-561.90%	0.17	7.60	78.80%	-1,029.40%	-667.77%
HLVX	HILLEVAX INC	$97.27M	-75.30%	-58.60%	-81.68%	-107.30%	0.25	10.84	N/A	N/A	N/A
MBRX	MOLECULIN BIOTECH INC	$14.84M	-165.00%	-90.00%	-188.16%	898.10%	1.83	0.97	N/A	N/A	N/A
CELU	CELULARITY INC	$33.50M	-119.50%	-25.40%	-56.82%	-27.90%	6.46	0.19	56.80%	-72.70%	-62.09%
ARWR	ARROWHEAD PHARMACEUTICALS INC	$1.75B	-243.20%	-64.10%	-64.18%	-52.30%	18.21	6.09	100.00%	-25,588.60%	-23,617.36%
MLYS	MINERALYS THERAPEUTICS INC	$708.16M	-68.00%	-62.40%	-92.97%	-105.10%	0.08	14.02	N/A	N/A	N/A
IDYA	IDEAYA BIOSCIENCES INC	$1.76B	-26.70%	-25.50%	-25.46%	-32.20%	0.06	14.97	100.00%	-3,921.10%	-3,921.10%
BBIO	BRIDGEBIO PHARMA INC	$7.28B	N/A	-82.00%	-75.23%	-26.00%	-1.53	4.57	95.40%	-524.20%	-430.76%
CRBU	CARIBOU BIOSCIENCES INC	$79.15M	-50.20%	-41.50%	-52.75%	-46.40%	0.24	7.16	100.00%	-1,491.90%	-1,492.04%
QNRX	QUOIN PHARMACEUTICALS LTD	$6.97M	-114.70%	-62.60%	-77.74%	-128.30%	0.71	3.57	N/A	N/A	N/A
IMNM	IMMUNOME INC	$764.30M	-125.30%	-105.30%	-157.56%	-520.50%	0.33	4.08	100.00%	-3,240.40%	-3,240.38%
DBVT	DBV TECHNOLOGIES SA	$246.78M	-278.20%	-140.50%	-1,116.57%	-708.30%	16.60	0.72	100.00%	-3,250.00%	-3,249.79%
ATRA	ATARA BIOTHERAPEUTICS INC	$46.81M	N/A	-63.90%	317.16%	-457.30%	-2.12	0.48	83.70%	-66.20%	-62.66%
NGNE	NEUROGENE INC	$223.94M	-38.90%	-34.40%	-23.44%	-73.60%	0.08	20.84	N/A	N/A	N/A
MBX	MBX BIOSCIENCES INC	$350.62M	-67.00%	-35.10%	-24.05%	-47.90%	0.04	24.19	N/A	N/A	N/A
CLSD	CLEARSIDE BIOMEDICAL INC	$66.73M	N/A	-107.00%	-168.96%	-64.20%	-1.65	4.44	91.00%	-2,064.40%	-2,064.42%
TNXP	TONIX PHARMACEUTICALS HOLDING CORP	$115.89M	-142.90%	-112.20%	-89.94%	-189.60%	0.17	6.50	23.10%	-1,288.30%	-1,288.25%
URGN	UROGEN PHARMA LTD	$536.54M	-7,363.60%	-47.40%	-46.51%	-61.90%	-33.46	6.01	90.20%	-140.40%	-123.37%
NKTX	NKARTA INC	$150.43M	-24.60%	-20.10%	-22.56%	-22.30%	0.23	14.45	N/A	N/A	N/A
TVGN	TEVOGEN BIO HOLDINGS INC	$189.41M	N/A	-284.90%	180.78%	194.90%	-1.52	0.26	N/A	N/A	N/A
TELO	TELOMIR PHARMACEUTICALS INC	$75.89M	-1,166.50%	-829.70%	-1,896.34%	3,068.20%	1.06	1.94	N/A	N/A	N/A
VERV	VERVE THERAPEUTICS INC	$503.47M	-37.30%	-29.00%	-32.81%	-35.60%	0.31	12.65	100.00%	-614.60%	-613.51%
DRMA	DERMATA THERAPEUTICS INC	$4.55M	-366.00%	-238.20%	N/A	-2,976.20%	1.26	N/A	N/A	N/A	N/A
MTSR	METSERA INC	$2.53B	N/A	-67.50%	-56.88%	646.60%	-0.65	5.34	N/A	N/A	N/A
INMB	INMUNE BIO INC	$180.23M	-124.40%	-87.80%	-130.12%	736.70%	0.23	3.14	100.00%	-300,585.70%	-300,585.71%
SXTP	60 DEGREES PHARMACEUTICALS INC	$3.95M	-166.00%	-130.30%	-193.53%	-291.20%	0.45	3.25	43.50%	-1,237.30%	-1,165.19%
BEAM	BEAM THERAPEUTICS INC	$1.67B	-45.80%	-30.80%	-40.87%	-40.50%	0.51	4.82	100.00%	-593.10%	-593.06%
NAUT	NAUTILUS BIOTECHNOLOGY INC	$86.92M	-31.90%	-27.40%	-31.28%	-27.40%	0.17	17.36	N/A	N/A	N/A
DSGN	DESIGN THERAPEUTICS INC	$275.87M	-19.30%	-18.70%	-20.35%	-21.70%	0.04	29.31	N/A	N/A	N/A
KRRO	KORRO BIO INC	$166.65M	-48.50%	-36.40%	-39.49%	-49.80%	0.41	8.79	100.00%	-3,680.40%	-3,674.15%
CLYM	CLIMB BIO INC	$90.42M	-38.90%	-38.20%	-34.82%	-148.50%	0.03	31.41	N/A	N/A	N/A
DMAC	DIAMEDICA THERAPEUTICS INC	$177.85M	-51.90%	-47.70%	-59.61%	-58.20%	0.14	8.28	N/A	N/A	N/A
ATOS	ATOSSA THERAPEUTICS INC	$115.99M	-32.80%	-30.60%	-35.68%	-7,829.30%	0.07	14.99	N/A	N/A	N/A
COEP	COEPTIS THERAPEUTICS HOLDINGS INC	$28.27M	-329.10%	-124.80%	-214.26%	-207.40%	1.58	0.23	N/A	N/A	N/A
PRTG	PORTAGE BIOTECH INC	$13.22M	-674.40%	-415.80%	-4,189.58%	-646.10%	1.44	3.08	N/A	N/A	N/A
VSTM	VERASTEM INC	$385.64M	-2,003.60%	-114.30%	-178.40%	-380.90%	-4.51	3.07	100.00%	-1,306.40%	-1,258.90%
STRO	SUTRO BIOPHARMA INC	$87.96M	-224.10%	-52.50%	-78.07%	-95.20%	7.68	2.60	100.00%	-366.60%	-321.25%
ALLO	ALLOGENE THERAPEUTICS INC	$365.00M	-55.30%	-43.50%	-50.07%	-53.20%	0.30	8.54	100.00%	-1,170,863.60%	-1,168,027.27%
PRAX	PRAXIS PRECISION MEDICINES INC	$758.94M	-49.50%	-46.00%	-41.03%	-90.60%	0.09	10.77	100.00%	-2,137.50%	-2,137.48%
JANX	JANUX THERAPEUTICS INC	$1.96B	-9.20%	-8.80%	-6.61%	-11.10%	0.04	59.21	100.00%	-651.60%	-651.62%
XENE	XENON PHARMACEUTICALS INC	$2.92B	-28.50%	-27.30%	-31.27%	-32.50%	0.06	17.85	N/A	N/A	N/A
ADTX	ADITXT INC	$2.56M	-852.50%	-156.40%	-413.91%	-225.30%	48.05	0.09	-368.30%	-34,526.60%	-26,991.66%
ANRO	ALTO NEUROSCIENCE INC	$67.41M	-35.60%	-31.60%	-35.85%	-662.20%	0.17	16.92	N/A	N/A	N/A
TRVI	TREVI THERAPEUTICS INC	$668.07M	-64.50%	-57.70%	-47.75%	-84.00%	0.11	10.41	N/A	N/A	N/A
DAWN	DAY ONE BIOPHARMACEUTICALS INC	$788.54M	-23.00%	-20.00%	-17.35%	-61.60%	0.16	7.66	96.00%	-72.80%	-67.36%
PEPG	PEPGEN INC	$51.33M	-61.00%	-49.90%	-67.52%	-82.90%	0.27	7.41	N/A	N/A	N/A
VRAX	VIRAX BIOLABS GROUP LTD	$4.26M	-87.90%	-79.90%	-76.29%	-444.40%	0.12	11.58	39.60%	-7,753.20%	-7,864.33%
SLN	SILENCE THERAPEUTICS PLC	$174.56M	-64.80%	-20.30%	-23.93%	-59.40%	-0.51	11.14	72.70%	-104.70%	-102.79%
SANA	SANA BIOTECHNOLOGY INC	$427.55M	-84.80%	-45.20%	-58.55%	-90.60%	1.00	3.54	N/A	N/A	N/A
AVTX	AVALO THERAPEUTICS INC	$53.15M	-502.60%	-29.20%	-26.66%	42.50%	0.13	19.96	183.00%	-7,965.80%	-8,692.06%
MBIO	MUSTANG BIO INC	$3.60M	N/A	-159.10%	477.04%	190.00%	-3.40	0.68	N/A	N/A	N/A
IGMS	IGM BIOSCIENCES INC	$82.79M	-190.70%	-61.00%	-85.85%	-72.50%	4.52	5.14	100.00%	-7,308.50%	-7,308.51%
CRBP	CORBUS PHARMACEUTICALS HOLDINGS INC	$91.37M	-31.20%	-26.90%	-26.61%	-31.50%	0.09	12.94	N/A	N/A	N/A
CNSP	CNS PHARMACEUTICALS INC	$3.19M	-7,384.30%	-293.60%	-240.29%	416.80%	0.41	3.43	N/A	N/A	N/A
RNA	AVIDITY BIOSCIENCES INC	$3.92B	-25.90%	-23.40%	-21.99%	-36.40%	0.10	15.74	100.00%	-2,957.70%	-2,957.71%
GANX	GAIN THERAPEUTICS INC	$56.96M	-222.60%	-135.50%	-242.00%	1,091.80%	0.65	2.97	N/A	N/A	N/A
NTLA	INTELLIA THERAPEUTICS INC	$918.20M	-54.00%	-43.10%	-48.05%	-48.10%	0.37	5.77	100.00%	-896.80%	-896.77%
ZNTL	ZENTALIS PHARMACEUTICALS INC	$101.97M	-43.30%	-34.40%	-43.87%	-39.10%	0.28	7.32	N/A	N/A	N/A
NNVC	NANOVIRICIDES INC	$21.43M	-87.90%	-78.70%	-90.16%	-147.60%	0.11	3.44	N/A	N/A	N/A
VTGN	VISTAGEN THERAPEUTICS INC	$67.54M	-48.10%	-43.80%	-57.20%	-629.10%	0.14	9.35	100.00%	-6,774.20%	-6,773.01%
SRRK	SCHOLAR ROCK HOLDING CORP	$3.12B	-128.90%	-85.80%	-57.55%	-122.80%	0.29	9.61	N/A	N/A	N/A
FBLG	FIBROBIOLOGICS INC	$42.26M	N/A	-94.50%	-299.57%	275.40%	5.01	1.12	N/A	N/A	N/A
AMLX	AMYLYX PHARMACEUTICALS INC	$452.76M	-127.50%	-101.10%	-182.86%	-215.00%	0.18	6.67	-42.60%	-345.40%	-345.81%
ACET	ADICET BIO INC	$54.74M	-52.50%	-45.60%	-58.32%	-119.50%	0.18	9.29	N/A	N/A	N/A
OMER	OMEROS CORP	$426.77M	N/A	-45.30%	-66.89%	-18.30%	-2.52	1.69	N/A	N/A	N/A
CRSP	CRISPR THERAPEUTICS AG	$3.32B	-18.50%	-15.80%	-16.83%	-18.10%	0.16	22.07	100.00%	-981.50%	-971.93%
OLMA	OLEMA PHARMACEUTICALS INC	$352.60M	-48.30%	-43.20%	-31.64%	-60.50%	0.10	10.50	N/A	N/A	N/A
APVO	APTEVO THERAPEUTICS INC	$772.98k	-488.90%	-152.50%	-257.14%	-395.60%	2.28	1.72	N/A	N/A	N/A
MNPR	MONOPAR THERAPEUTICS	$255.63M	-84.80%	-75.60%	-28.32%	-800.60%	0.10	11.48	N/A	N/A	N/A
EWTX	EDGEWISE THERAPEUTICS INC	$1.56B	-26.80%	-25.70%	-28.90%	-28.70%	0.06	19.93	N/A	N/A	N/A
DNA	GINKGO BIOWORKS HOLDINGS INC	$427.71M	-65.60%	-36.10%	-43.10%	-55.30%	0.92	5.62	80.40%	-240.90%	-241.11%
REVB	REVELATION BIOSCIENCES INC	$2.76M	-334.30%	-149.10%	-319.40%	277.60%	0.41	3.43	N/A	N/A	N/A
AGIO	AGIOS PHARMACEUTICALS INC	$1.70B	58.90%	53.10%	45.38%	64.10%	0.08	11.90	88.60%	1,845.90%	1,967.15%
OSTX	OS THERAPIES INC	$43.98M	N/A	-439.50%	-749.45%	99.80%	-0.90	1.20	N/A	N/A	N/A

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in May 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

1. Protalix Biotherapeutics (NYSEMKT:PLX)

Protalix Biotherapeutics (NYSEMKT:PLX) is the #1 top biotech stock out of 661 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Protalix Biotherapeutics (NYSEMKT:PLX) is: Value: B, Growth: A, Momentum: B, Sentiment: A, Safety: C, Financials: B, and AI: A.

Protalix Biotherapeutics (NYSEMKT:PLX) has a Due Diligence Score of 23, which is -1 points lower than the biotech industry average of 24. Although this number is below the industry average, our proven quant model rates PLX as a "A".

PLX passed 7 out of 33 due diligence checks and has weak fundamentals. Protalix Biotherapeutics has seen its stock return 169.3% over the past year, overperforming other biotech stocks by 246 percentage points.

Protalix Biotherapeutics has an average 1 year price target of $15.00, an upside of 388.6% from Protalix Biotherapeutics's current stock price of $3.07.

Protalix Biotherapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Protalix Biotherapeutics, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Aurinia Pharmaceuticals (NASDAQ:AUPH)

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #2 top biotech stock out of 661 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 57, which is 33 points higher than the biotech industry average of 24.

AUPH passed 19 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 61.89% over the past year, overperforming other biotech stocks by 139 percentage points.

3. Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ:CPRX) is the #3 top biotech stock out of 661 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Catalyst Pharmaceuticals (NASDAQ:CPRX) is: Value: A, Growth: C, Momentum: C, Sentiment: A, Safety: D, Financials: A, and AI: B.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a Due Diligence Score of 76, which is 52 points higher than the biotech industry average of 24.

CPRX passed 25 out of 33 due diligence checks and has strong fundamentals. Catalyst Pharmaceuticals has seen its stock return 61.4% over the past year, overperforming other biotech stocks by 138 percentage points.

Catalyst Pharmaceuticals has an average 1 year price target of $33.20, an upside of 36.68% from Catalyst Pharmaceuticals's current stock price of $24.29.

Catalyst Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Catalyst Pharmaceuticals, 60% have issued a Strong Buy rating, 40% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Dominari Holdings (NASDAQ:DOMH)

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 6.97%, which is 5 percentage points higher than the biotech industry average of 1.92%.

Dominari Holdings's dividend payout ratio of -13.4% indicates that its high dividend yield might not be sustainable for the long-term.

2. Novo Nordisk (Ozempic) (NYSE:NVO)

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.43%, which is 1 percentage points higher than the biotech industry average of 1.92%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 45.5% indicates that its dividend yield is sustainable for the long-term.

3. Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.31%, which is -1 percentage points lower than the biotech industry average of 1.92%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 43.8% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 1.74% in the last day, and up 4.52% over the last week. Regulus Therapeutics was the among the top gainers in the biotechnology industry, gaining 136.8% yesterday.

Regulus Therapeutics shares are trading higher after the company announced it entered into an agreement to be acquired by Novartis AG for $7 in cash per share.

What are the most undervalued biotech stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

1. Harmony Biosciences Holdings (NASDAQ:HRMY)

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -4.66% in the past year. It has overperformed other stocks in the biotech industry by 72 percentage points.

2. Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has dropped -37.28% in the past year. It has overperformed other stocks in the biotech industry by 40 percentage points.

3. Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Jazz Pharmaceuticals has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Jazz Pharmaceuticals's stock has gained 5.61% in the past year. It has overperformed other stocks in the biotech industry by 82 percentage points.

Are biotech stocks a good buy now?

54.79% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 100.94% over the next year.

1.74% of biotech stocks have a Zen Rating of A (Strong Buy), 4.14% of biotech stocks are rated B (Buy), 42.05% are rated C (Hold), 36.38% are rated D (Sell), and 15.69% are rated F (Strong Sell).

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is -162.28x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.